We are pleased to announce that The Arcady Group has been awarded two new contracts from the Bill & Melinda Gates Foundation and that a third contract with the foundation has been extended and supplemented.
In connection with the first contract, extending through June 30, 2024, the Arcady Group will provide strategic chemistry, manufacturing, and controls (“CMC”) consulting services to the Bill & Melinda Gates Foundation on drug products intended for global health purposes. Under the second contract, extending through December 31, 2025, the Arcady Group will monitor, report on, and seek to understand and address affordability, adherence, and similar delivery, access, and uptake issues relating to new, optimized TB formulations. Finally, the third contract, pursuant to which the Arcady Group has been providing subject matter expert support for activities and investments relating to Wolbachia vector control technologies to mitigate the burden and health impact of dengue, has been supplemented and extended through December 31, 2023.
It is expected that these will be the last contracts will be the last to be accepted and performed by the Arcady Group, as its Founder and Managing Director, Bruce Thomas, has announced his intention to
retire following successful completion of these contracts.